Targeted Therapies Advanced for Breast Cancer
New clinical data updates the treatment landscape for patients with advanced breast cancer.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Do you trust that new medical research is significantly improving cancer treatment options for patients?
Researchers have evaluated several targeted therapies for advanced breast cancer, highlighting both successes and challenges in clinical trials. The FDA approved inavolisib in 2024 to improve outcomes for patients with specific genetic mutations.
Why it matters
Understanding the efficacy of new targeted therapies helps clinicians navigate complex treatment decisions for advanced breast cancer. These developments represent a shift in how providers approach patients with specific PIK3CA-mutated disease profiles.
In 2024, the FDA approved inavolisib plus palbociclib and fulvestrant based on clinical evidence showing improved outcomes compared to standard palbociclib and fulvestrant therapy. Meanwhile, trials like persevERA and SERENA-4 did not show superior survival.
The players
Matthew Goetz
Matthew Goetz is a clinical researcher at the Mayo Clinic Comprehensive Cancer Center who studies targeted therapies for breast cancer.
Mayo Clinic Comprehensive Cancer Center
The Mayo Clinic Comprehensive Cancer Center is a medical institution that conducts research and provides care for various forms of cancer.
The details
New therapies, such as BTX-9341, aim to remove CDK4 and CDK6 proteins through targeted degradation. While inavolisib provides a new option for patients with PIK3CA-mutated disease, the use of other treatments like alpelisib remains limited due to adverse effect profiles.
Timeline
The FDA approved inavolisib for specific breast cancer patients in 2024.
The Big Picture
These findings build upon the results of the INAVO120 trial, which established the clinical framework for the current standard of care involving inavolisib. This development marks a transition toward more precise, mutation-specific treatment protocols in oncology.
The approval of inavolisib provides a new treatment option for patients diagnosed with PIK3CA-mutated breast cancer. Patients should discuss potential side effects and eligibility for these targeted therapies with their oncology care team.
The takeaway
Targeted therapies continue to evolve as researchers identify ways to bypass traditional treatment limitations. Patients and providers should regularly review the latest clinical trial data to stay informed about emerging options for advanced disease.
Further reading
For more information on current treatment standards, visit the United States Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that new medical research is significantly improving cancer treatment options for patients?
